Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase I Study: MTI-301 in Advanced/Metastatic/Refractory Solid Tumors
Mayo Clinic is assessing MTI-301—a first-in-human SCD1 inhibitor—as monotherapy in patients with unresectable or metastatic solid tumors with no standard care options. Participants receive MTI-301 orally once daily…
NCT06911008 - New trial
Multiple solid tumors
Phase 1 Study of TGW101 in Advanced Solid Tumors
Tagworks Pharmaceuticals BV is evaluating TGW101—a TAG72-directed antibody-drug conjugate administered via IV infusion followed by TRG001—in a first-in-human study in patients with various advanced solid tumors,…
NCT06959706 - New trial
Multiple solid tumors
Phase I Study: BNT317 in Advanced Solid Tumors
BioNTech SE is conducting a first-in-human, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of BNT317—a CD39-directed monoclonal antibody—as monotherapy in…
NCT06750185 - New trial
Multiple solid tumors
Phase I/II Study of IPN01195 in Advanced Solid Tumours with MAPK Alterations
Ipsen is evaluating IPN01195—a MAPK1 inhibitor—as monotherapy in adults with advanced solid tumours (with MAPK alterations) who have no standard care options. The study includes a dose-escalation phase to determine…
NCT06833008 - New trial
Multiple solid tumors
Phase 1 Study of IBI3020 in Advanced Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. is evaluating IBI3020—a CEACAM5-directed monoclonal antibody—in a multicenter, open-label Phase 1 trial for patients with unresectable, locally advanced or…
NCT06963281 - New trial
Multiple solid tumors
Phase I/1b Study: ODC-IL2 in Advanced Solid Tumors
Trutino Biosciences Inc. is conducting a first-in-human, multicenter, open-label trial to evaluate the safety, pharmacodynamics, pharmacokinetics, and antitumor activity of ODC-IL2—a conditionally activated IL-2…
NCT06770764 - New trial
Multiple solid tumors
Multicenter Phase 2/3 Study of Ficerafusp Alfa With Pembrolizumab in First-Line PD-L1+ HNSCC
Bicara Therapeutics is evaluating the safety and efficacy of ficerafusp alfa—a dual EGFR/TGFβ inhibitor—combined with pembrolizumab versus placebo plus pembrolizumab in first-line treatment of PD-L1-positive…
NCT06788990 - New trial
Multiple solid tumors
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal SCC
This phase 2 trial is evaluating the safety and tolerability of three CUE-101 dosing schedules as neoadjuvant therapy in HLA-A*0201 positive, HPV16+ oropharyngeal SCC patients before they receive standard definitive…
NCT04852328 - New trial
Multiple solid tumors
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
MSK is running a phase I trial combining fixed-dose ruxolitinib with dose-escalated duvelisib to assess safety and early signals of efficacy in relapsed/refractory NK/T-cell lymphomas, including ALCL and CTCL. The…
NCT05010005 - New trial
Multiple solid tumors
A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University is evaluating whether adding zanzalintinib to eribulin can improve progression-free survival in patients with advanced liposarcoma and leiomyosarcoma resistant to standard therapies by exploring…
NCT06957431 - New trial
Multiple solid tumors
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment with HER2-targeted Therapy
This pilot study is assessing whether the PET tracer [68Ga]Ga-ABY-025 can enhance detection and visualization of lesions in HER2+ solid tumors during standard HER2-targeted treatment. Vanderbilt is leading the trial…
NCT06828588 - New trial
Multiple solid tumors
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Previously Treated Metastatic Colorectal Cancer
MD Anderson is sponsoring a Phase II trial to evaluate ivonescimab—a bispecific antibody targeting PD-1 and VEGF—in advanced metastatic colorectal cancer patients with distinct mismatch repair statuses, using a…
NCT06959550 - New trial
Multiple solid tumors
Phase 2 Basket Study Evaluating BAY2927088 in HER2-Activated Solid Tumors
Bayer is assessing BAY2927088—an oral EGFR and HER2 inhibitor—in adults with metastatic or unresectable solid tumors harboring HER2-activating mutations, including colorectal, biliary, bladder, cervical, and…
NCT06760819 - New trial
Multiple solid tumors
Assessment of Radiation-Induced Vascular Complications in H&N Cancers with PET/CT Imaging
Emory is investigating whether F-18 NaF PET/CT can more effectively assess radiation-induced vascular effects in head and neck cancer patients compared to the standard F-18 FDG PET/CT. The trial targets patients with…
NCT06914999 - New trial
Multiple solid tumors
A Randomized, Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and T-DXd Versus Trastuzumab, Chemotherapy, and Pembrolizumab for HER2+ Gastric Cancer (ARTEMIDE-Gastric01)
This global Phase III trial is evaluating rilvegostomig combined with T‑DxD and fluoropyrimidine against standard regimens, including trastuzumab and pembrolizumab, as first-line therapy for HER2-positive advanced…
NCT06764875 - New trial
Multiple solid tumors
Phase 1/2 Trial of ENV-501 in Advanced HER3-Expressing Solid Tumors
Endeavor is conducting a first‐in‐human, open‐label study assessing ENV-501’s safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced relapsed/refractory HER3-positive breast, NSCLC, and…
NCT06956690 - New trial
Multiple solid tumors
Single Center Observational Study Using Spinal Laser Interstitial Thermal Therapy (sLITT) in the Treatment of Spine Metastases and Tumors
This observational study aims to assess the efficacy and safety of spinal laser interstitial thermal therapy for definitive treatment of metastases and tumors, comparing its tumor control rates with conventional open…
NCT06548061 - Trial result
Multiple solid tumors
Nonoperative Management of Early-Stage dMMR Tumors Offers Organ Preservation
A phase 2 trial with 117 patients having stage I–III mismatch repair-deficient (dMMR) solid tumors, including locally advanced rectal and other nonrectal cancers, evaluated neoadjuvant PD-1 blockade with dostarlimab.…
- Trial result
Multiple solid tumors
Next-Generation KRAS G12C Inhibitor D3S-001 Demonstrates Robust Activity in Advanced Solid Tumors
In this phase 1 trial, D3S-001 was evaluated in KRAS G12C-mutant advanced tumors (42 patients in the dose-escalation phase and 20 NSCLC patients pretreated with prior G12C inhibitors) and exhibited dose-dependent…
- New trial
Multiple solid tumors
Phase II Trial: DB-1311 Combinations in Advanced/Metastatic Solid Tumors
DualityBio Inc. is assessing the safety and efficacy of DB-1311 – a B7-H3-directed ADC – in combination with either BNT327 (a VEGFA-directed mAb) or DB-1305 (a HER2-directed ADC) across multiple advanced solid tumors…
NCT06953089 - New trial
Multiple solid tumors
Pilot Study: Proton SBRT for Complex Spinal Metastases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is evaluating proton stereotactic body radiotherapy for nonhematologic spinal metastases in patients with complex lesions that cannot be effectively treated…
NCT06895564 - New trial
Multiple solid tumors
First-in-Human Study: TYRA-430 in FGFR-Driven Advanced Cancers
Tyra Biosciences, Inc. is evaluating TYRA-430—a novel FGFR4 inhibitor—as monotherapy in a dose-escalation and expansion study in patients with advanced hepatocellular carcinoma and other solid tumors harboring…
NCT06915753 - New trial
Multiple solid tumors
Phase 1a/1b Study of PHST001 in Advanced Relapsed/Refractory Solid Tumors
Pheast Therapeutics is investigating PHST001 in an open-label, dose escalation and expansion trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and antitumor activity, and to determine the recommended…
NCT06840886 - New trial
Multiple solid tumors
Phase III Trial: Pafolacianine for Localization of Pediatric Extracranial Solid Tumors
Mayo Clinic is evaluating pafolacianine—an IV-administered, folate receptor-targeted fluorescent imaging agent used with near infrared (NIR) imaging—to enhance the identification of cancerous lesions during standard…
NCT06915727 - New trial
Multiple solid tumors
Phase II Trial: Photon-VMAT Craniospinal Irradiation for Leptomeningeal Disease
City of Hope Medical Center is evaluating photon volumetric modulated arc therapy for craniospinal irradiation as a treatment for leptomeningeal disease secondary to breast cancer or NSCLC, with patients receiving…
NCT06910761 - New trial
Multiple solid tumors
Phase 1 Study: BGB-B455 in CLDN6-Positive Advanced Solid Tumors
BeiGene is investigating BGB-B455—a CLDN6-directed CD3 activator bispecific antibody—as monotherapy in patients with advanced or metastatic solid tumors with no standard care options. This open-label study includes a…
NCT06803680 - New trial
Multiple solid tumors
Phase 1 Trial of QTX3544 in KRAS G12V Advanced Solid Tumors
Quanta Therapeutics is evaluating QTX3544—a KRAS inhibitor—both as monotherapy and in combination with cetuximab in patients with advanced solid tumors harboring KRAS G12V mutations through dose escalation and…
NCT06715124 - New trial
Multiple solid tumors
Phase I/II Study: AZD4360 in CLDN18.2-Positive Advanced Solid Tumors
AstraZeneca is evaluating AZD4360—a CLDN18.2 and CD3 directed bispecific antibody—as monotherapy in adult patients with locally advanced or metastatic solid tumors (gastric/GEJ, biliary tract, and PDAC) that express…
NCT06921928 - New trial
Multiple solid tumors
Phase I Study: BAY 3713372 in MTAP-deleted Solid Tumors
Bayer is conducting a first-in-human dose-escalation study to evaluate BAY 3713372—a novel second-generation PRMT5 inhibitor targeting MTAP-deleted solid tumors. The study will assess the safety, tolerability,…
NCT06914128 - Trial result
Multiple solid tumors
Triple DDR Assault: ART0380 and Low-Dose Irinotecan Yield High Responses in ATM-Negative Tumors
In this first-in-human study, advanced cancer patients received ART0380 (ATR inhibitor) with low-dose irinotecan, with the recommended phase 2 dose established at 200mg ART0380 on days 1-3 and 8-10 and irinotecan at…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.